The LN229 cell line is a human glioblastoma multiforme (GBM) cell line derived from a patient with a malignant brain tumor. Glioblastoma multiforme is the most common and aggressive primary brain tumor in adults, characterized by rapid growth and resistance to conventional treatments. The LN229 cell line is widely used in cancer research, particularly in the study of brain cancer biology, drug resistance, and the development of novel therapeutic strategies.
Researchers use the LN229 cell line for various purposes, such as:
- Investigating the molecular mechanisms underlying glioblastoma development and progression.
- Studying the cellular response to chemotherapeutic agents, radiation, and targeted therapies, as well as developing strategies for overcoming drug resistance.
- Evaluating the efficacy of novel anticancer therapeutics and treatment strategies in vitro before testing them in in-vivo models.
- Identifying and validating potential therapeutic targets and biomarkers for glioblastoma.
The use of the LN229 cell line, along with other glioblastoma cell lines, has contributed significantly to advancing our understanding of glioblastoma biology and has aided in the development of more effective treatment options for patients.